These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36389024)

  • 1. Value Insider Season 1 Episode 4: How are Costs Measured, and How are CEAs Constructed and Used? (CEA) [Podcast].
    Rutten-van Mölken MPMH; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8055-8061. PubMed ID: 36389024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value Insider Season 1 Episode 2: How to Measure Quality of Life and Utility? (QoL) [Podcast].
    Devlin NJ; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7773-7779. PubMed ID: 36263308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast].
    Drummond MF; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7487-7492. PubMed ID: 36213303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast].
    Kanavos PG; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8429-8435. PubMed ID: 36518234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast].
    Garrison LP; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8217-8224. PubMed ID: 36451799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast].
    Sullivan SD; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7879-7884. PubMed ID: 36325498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
    Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
    Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-, under- and misuse of pain treatment in Germany.
    Dietl M; Korczak D
    GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone graft substitutes for the treatment of traumatic fractures of the extremities.
    Hagen A; Gorenoi V; Schönermark MP
    GMS Health Technol Assess; 2012; 8():Doc04. PubMed ID: 22984371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports].
    Di Nardo F; Boccalini S; Calabrò GE; Marcellusi A; Ruggeri M; Bonanni P; Vitali R; Capannini E; Mennini FS; Cicchetti A; Panatto D; Gasparini R; Ricciardi W; De Waure C
    Ig Sanita Pubbl; 2017; 73(5):453-471. PubMed ID: 29433132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital interventions in mental health: evidence syntheses and economic modelling.
    Gega L; Jankovic D; Saramago P; Marshall D; Dawson S; Brabyn S; Nikolaidis GF; Melton H; Churchill R; Bojke L
    Health Technol Assess; 2022 Jan; 26(1):1-182. PubMed ID: 35048909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transferability of Economic Evaluations of Treatments for Advanced Melanoma.
    Gorry C; McCullagh L; Barry M
    Pharmacoeconomics; 2020 Feb; 38(2):217-231. PubMed ID: 31761996
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.